Given the promising data of LD IL-2 in patients with HCV, GVHD, and Alopecia areata, there is great interest in giving LD IL-2 to patients with T1D to specifically boost Treg numbers and activity (15, 16, 62). This evidence concerns the gene IL2 and graft versus host disease.